Learning from oncocytic tumors: Why choose inefficient mitochondria?
about
Targeting hypoxic response for cancer therapyAutophagy-mediated tumor promotionTargeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancersSomatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors.Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells.BAP1 loss defines a new class of renal cell carcinoma.Molecular pathways: autophagy in cancer--a matter of timing and context.Mitophagy and cancer.A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors.The role for autophagy in cancer.High copy number of mitochondrial DNA (mtDNA) predicts good prognosis in glioma patients.High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants.Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dubé tumorsRelevance of mitochondrial genetics and metabolism in cancer development.The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to TumorigenesisParkinson's disease: a complex interplay of mitochondrial DNA alterations and oxidative stress.Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis.Mitochondrial dysfunction and permeability transition in osteosarcoma cells showing the Warburg effect.Recent insights into the function of autophagy in cancer.Extra-tongue oral granular cell tumor: Histological and immunohistochemical aspect.Exploiting the bad eating habits of Ras-driven cancers.Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism.Mitochondria and Cancer.Autophagy and p53.Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors.Mitochondrial ribosomes in cancer.Mitochondrial Oxidative Stress due to Complex I Dysfunction Promotes Fibroblast Activation and Melanoma Cell Invasiveness.Familial Cancers of Head and Neck Region.Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours.High level of oxidized nucleosides in thyroid mitochondrial DNA; damaging effects of Fenton reaction substrates.Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma.Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas.Site-specific selection reveals selective constraints and functionality of tumor somatic mtDNA mutations.Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione.Non-Canonical Mechanisms Regulating Hypoxia-Inducible Factor 1 Alpha in Cancer.PGC1α: Friend or Foe in Cancer?Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma.Oncocytic Adrenocortical Neoplasm with Concomitant Papillary Thyroid Cancer.Increased copy number of mitochondrial DNA predicts poor prognosis of esophageal squamous cell carcinoma.
P2860
Q26767351-F7BAA925-5ADE-4998-8C7F-DC205941407EQ27011920-8E13B7D5-6391-4AB8-9D8A-D944373EF247Q27022240-BE3C289A-6AB5-4954-8C86-9918353FBD25Q31048075-EA36891F-2478-49A1-A790-AB0F19ACFB02Q34258926-0E27D64C-97A8-45F3-A073-EC7209B13253Q34280223-2D2EC699-EDC1-44C5-81D2-DCECAF1FE8E7Q35044465-151DD123-903B-45E6-9778-89D5A80F8BECQ35215652-85158F45-C6F6-4775-B969-9F19EF6C31C6Q35218596-2A4E928E-9DA8-402C-A00B-0C3BF3840F9BQ35242506-A27CD211-1572-4E43-BAA7-EF677A08A9E3Q35666483-016A240F-16D3-4156-9822-AE8AB7DFF24BQ35929824-12DDD529-1665-4BF0-88E6-730B0402F291Q36235955-FA5FDBEF-D773-439F-8970-4FC6752540F1Q36555188-674111C0-A083-44D0-91DE-AEFB2F41D2ADQ36654206-9CF720A5-7EA0-46F0-91CF-62920740367AQ36655956-2C07086F-0AB9-4B4C-BAC0-EA7DC14111ACQ37019194-941FED7E-CFA3-4B7B-8AE1-769955F890E8Q37311426-18D90E64-960A-4406-8462-2491F3F1120FQ37343004-439ED65D-847A-447B-8D1E-A35C9911DB5DQ37566768-FDD6FDD5-97D2-4718-A123-8DD7BA23D57EQ38151668-91F7013B-97C1-45FF-AB94-454116DEEEF4Q38662384-4A2E40F3-A9D9-4784-8734-9CB2E1C27F0DQ38760551-3302712C-DBF3-42D9-BA15-6331419312B9Q38796071-4E1E4F98-E07A-4DEF-BE22-DC3E48499156Q39107065-7106CEBA-0B6C-4FBB-932F-F923D3E345A7Q39264654-2C9EB21B-80FC-4249-A12F-EEF678CBFEA9Q40512512-B75BA0D6-0A22-400C-B533-0EE0117D9530Q41178179-FD42F6CC-51A6-4759-A9B5-0BA481796FECQ42642212-0F58F94B-FF77-4466-B39F-5E3F0AD72C7FQ43203893-09F0FBED-D053-48A6-B02F-CC68CE7D0C62Q43761846-AA208F7A-C8B2-42A2-86AD-E9CD9C98C3F1Q46098313-756F7237-8178-4F86-8AFB-834ADAA2FDBBQ46863464-503F0E27-7361-4158-A8D9-F917B8F66A37Q47107735-35E50504-9045-40DC-BA37-E538933F0BEFQ47131093-D3DEBC48-40BA-4DFB-9280-58EA20389BC5Q47160346-F2FCF0EE-BE3A-4D2C-980F-7EB31A9BD0C6Q47844268-244E201F-174A-4A33-ADE4-39A4670AF6DEQ48220009-F689D438-488C-40A2-B3BF-ECC95C3569D5Q49165379-F73A514F-EE5A-4CD9-BE3E-40E96746F05DQ49541978-2925238D-C3F9-43E2-9B2C-537976AD7DCB
P2860
Learning from oncocytic tumors: Why choose inefficient mitochondria?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Learning from oncocytic tumors: Why choose inefficient mitochondria?
@en
Learning from oncocytic tumors: Why choose inefficient mitochondria?
@nl
type
label
Learning from oncocytic tumors: Why choose inefficient mitochondria?
@en
Learning from oncocytic tumors: Why choose inefficient mitochondria?
@nl
prefLabel
Learning from oncocytic tumors: Why choose inefficient mitochondria?
@en
Learning from oncocytic tumors: Why choose inefficient mitochondria?
@nl
P2093
P1476
Learning from oncocytic tumors: Why choose inefficient mitochondria?
@en
P2093
Anna Maria Porcelli
Giovanni Romeo
Giuseppe Gasparre
P304
P356
10.1016/J.BBABIO.2010.08.006
P407
P577
2010-08-21T00:00:00Z